Phaseline

Companies › Zhejiang Raygene Pharmaceuticals

Zhejiang Raygene Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Apr 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
tirapazamine
Bioreductive hypoxic cytotoxin
UNKNOWNPhase 2HCCApr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06844357tirapazaminePhase 2HCCOncologyApr 2029

Targets

UNKNOWN (1)

Companies with the same targets

General Oncology Gilead Sciences Iterum Therapeutics, International Colgate Palmolive Vaxcyte

Companies built like this

NanoEcho Syncromune Galecto Biotech VSPharmTech BPGbio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.